Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 May;11(5):632-639.
doi: 10.1002/cpdd.1051. Epub 2022 Jan 7.

Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

Mark Johnson  1 , Teodora Pene Dumitrescu  2 , Samit R Joshi  3 , Ashwin Mathew  2 , Veronica Bainbridge  4 , Joyce Zhan  2 , Max Lataillade  3
Affiliations
Randomized Controlled Trial

Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

Mark Johnson et al. Clin Pharmacol Drug Dev. 2022 May.

Abstract

GSK3640254 is a next-generation maturation inhibitor with demonstrated potency across HIV-1 subtypes and a high barrier to emergent resistance. This phase I, 2-part, randomized, open-label study (ClinicalTrials.gov identifier, NCT04263142) in healthy participants assessed the relative bioavailability of a single dose of GSK3640254 200 mg in tablet and capsule formulations (part 1) and the effect of food on the pharmacokinetic profile of the tablet formulation (part 2). Overall, 39 participants were randomized to treatment (part 1, n = 18; part 2, n = 21). All participants in part 1 completed the study; 2 participants in part 2 withdrew before study completion (adverse event, n = 1; physician decision, n = 1). In part 1, plasma exposures of the GSK3640254 tablet formulation were not meaningfully different from those of the capsule formulation when administered in the presence of a moderate-fat meal. In part 2, GSK3640254 plasma exposures increased by ≈3- to 4-fold under high- and moderate-fat conditions, respectively, compared with fasted conditions. No major safety or tolerability findings were observed. The highest incidence of adverse events (24%) was reported under high-fat conditions. Taken together, these data support the use of the tablet formulation coadministered with food in the clinical development of GSK3640254 for treatment of HIV-1.

Keywords: GSK3640254; food effect; maturation inhibitor; pharmacokinetics; relative bioavailability.

PubMed Disclaimer

Conflict of interest statement

M.J., S.R.J., and M.L. are employees of ViiV Healthcare and may own stock in GlaxoSmithKline (GSK). A.M., V.B., and J.Z. are employees of and may own stock in GSK. T.P.D. was an employee of GSK during the conduct of the study and may own stock in GSK.

Figures

Figure 1
Figure 1
Structure of GSK3640254.
Figure 2
Figure 2
Study design schematics for (A) part 1 and (B) part 2.
Figure 3
Figure 3
Mean (SD) GSK3640254 plasma concentration–time plots by treatment in part 1: (A) linear and (B) semilogarithmic. Dashed line represents lower limit of quantification (3.00 ng/mL). SE, standard error.
Figure 4
Figure 4
Mean (SD) GSK3640254 plasma concentration–time plots by treatment in part 2: (A) linear and (B) semilogarithmic. Dashed line represents lower limit of quantification (3.00 ng/mL).
See this image and copyright information in PMC

References

    1. Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Curr Opin Virol. 2016;18:50‐56. - PubMed
    1. Arts EJ, Hazuda DJ. HIV‐1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012;2(4):a007161. - PMC - PubMed
    1. Morales‐Ramirez J, Bogner JR, Molina J‐M, et al. Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS‐955176) plus tenofovir/emtricitabine once daily in treatment‐naive HIV‐1‐infected adults: week 24 primary analysis from a randomized phase IIb trial. PLoS One. 2018;13(10):e0205368. - PMC - PubMed
    1. Wang D, Lu W, Li F. Pharmacological intervention of HIV‐1 maturation. Acta Pharm Sin B. 2015;5(6):493‐499. - PMC - PubMed
    1. Joshi SR, Fernando D, Igwe S, et al. Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor. Pharmacol Res Perspect. 2020;8(6):e00671. - PMC - PubMed

Publication types

Associated data